Shmuel Arnon

Prof. Dr. Shmuel Arnon

1. Department of Neonatology, Meir Medical Center, Kfar Saba 4428164, Israel
+2
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2014 in Acta Paediatrica
Verified
Journal Article
Closed access
PDF file
SAShmuel Arnon
Shmuel Arnon
CDChagit Diamant
Chagit Diamant
SBSofia Bauer
Sofia Bauer
RRRivka Regev
Rivka Regev
GSGisela Sirota
Gisela Sirota
ILIta Litmanovitz
Ita Litmanovitz

8 March 2007 in Journal of Perinatology
Verified
Journal Article
Closed access
SAShmuel Arnon
Shmuel Arnon
ILI Litmanovitz
I Litmanovitz
RRR H Regev
R H Regev
SBS Bauer
S Bauer
RSR Shainkin-Kestenbaum
R Shainkin-Kestenbaum
TDT Dolfin
T Dolfin

1 June 2008 in Current Opinion in Infectious Diseases
Verified
Journal Article
Closed access
SAShmuel Arnon
Shmuel Arnon
ILIta Litmanovitz
Ita Litmanovitz
The present review examines the major developments in early detection of neonatal sepsis, with an emphasis on the utility of diagnostic laboratory markers in clinical practice. Measures of acute phase proteins, cytokines, cell surface antigens, and bacterial genomes have been used alone or in combination to improve diagnosis of neonatal sepsis. Most studies evaluating laboratory diagnostic markers are retrospective cohorts or single center experience with relatively small sample size. Interpretation of these studies is confounded by inconsistent definitions of sepsis, heterogeneous sample populations, and different thresholds for diagnostic markers. Furthermore, many diagnostic markers are not available for routine care, they require specialized analytical procedures, and are expensive to perform. A better understanding of the neonatal inflammatory response to sepsis and identification of sensitive and specific markers of inflammation or rapid microbe-specific diagnostic tests would assist in the early detection of neonatal sepsis and in safely withholding antibiotics for patients in whom sepsis is unlikely.

1 February 2005 in Neonatology
Verified
Journal Article
Closed access
SAShmuel Arnon
Shmuel Arnon
ILIta Litmanovitz
Ita Litmanovitz
RRRivka Regev
Rivka Regev
SBSofia Bauer
Sofia Bauer
MLMonica Lis
Monica Lis
TDTzipora Dolfin
Tzipora Dolfin
Background: Few studies demonstrated that serum amyloid A (SAA), a non-specific acute-phase reactant, could be used as a reliable early marker for the diagnosis of late-onset sepsis (LOS). Objectives: To evaluate the diagnostic value and the dynamics of SAA levels during the course of LOS and to compare it to those of other inflammatory markers. Methods: Levels of SAA, C-reactive protein (CRP) and IL-6 together with clinical variables, biochemical parameters and cultures retrieved from all preterm infants suspected of LOS were checked at the first suspicion of sepsis and after 8, 24, 48 and 72 h. Results were compared to healthy, matched infants. Results: One hundred and sixteen infants were included in the study, 38 in the sepsis and 78 in the non-sepsis group. High levels of SAA were observed at sepsis onset, with a gradual decline thereafter, while CRP levels increased only at 24 h after sepsis onset. In the sepsis group, levels of SAA returned faster to baseline than CRP levels. Receiver-operating characteristic analysis values revealed that SAA at 10 µg/ml had the highest sensitivity at 0, 8 and 24 h after sepsis onset (95, 100 and 97%, respectively) and a negative predictive value (97, 100 and 98%, respectively). Conclusions: SAA is an accurate acute-phase protein during LOS in preterm infants. Quick and reliable SAA kits can make this marker a useful tool in LOS in preterm infants.

22 November 2021 in Children
Verified
Journal Article
Open access
PDF file
DYDana Yakobson
Dana Yakobson
CGChristian Gold
Christian Gold
BBBolette Daniels Beck
Bolette Daniels Beck
CECochavit Elefant
Cochavit Elefant
SBSofia Bauer-Rusek
Sofia Bauer-Rusek
SAShmuel Arnon
Shmuel Arnon
Unbuffered stress levels may negatively influence preterm-infants’ autonomic nervous system (ANS) maturation, thus affecting neurobehavior and psycho-emotional development. Music therapy (MT) is an evidence-based treatment modality in neonatal care. When coupled with skin-to-skin care (SSC), it may reduce stress responses in both preterm infants and their parents and enhance family-centered care. Accordingly, we aimed to compare the effects of combined MT and SSC and SSC alone on ANS stabilization in preterm infants. In a single-center, cluster-randomized trial design, ten two-month time-clusters were randomized to either combined MT and SSC or SSC alone. Families of preterm infants were offered two sessions of the allocated condition in the NICU, and a three-month follow up session at home. The primary outcome variable was stabilization of the ANS, defined by change in the high frequency (HF) power of heart rate variability (HRV) during the second session. Secondary outcomes included other HRV measures, parent–infant attachment, and parental anxiety at each session. Sixty-eight families were included. MT combined with SSC improved infants’ ANS stability, as indicated by a greater increase in HF power during MT compared to SSC alone (mean difference 5.19 m2/Hz, SE = 1.27, p < 0.001) (95% confidence interval 0.87 to 2.05). Most secondary outcomes were not significantly different between the study groups. MT contributes to preterm-infants’ autonomic stability, thus laying an important foundation for neuro-behavioral and psycho-emotional development. Studies evaluating longer-term effects of MT on preterm infants’ development are warranted.

26 January 2002 in Journal of Perinatal Medicine
Verified
Journal Article
Closed access
SAShmuel Arnon
Shmuel Arnon
ILI. Litmanovitz
I. Litmanovitz
RRR. Regev
R. Regev
MLM. Lis
M. Lis
RSR. Shainkin-Kestenbaum
R. Shainkin-Kestenbaum
TDT. Dolfin
T. Dolfin
In order to evaluate serum amyloid A as an early diagnostic marker of late-onset sepsis, seventy-nine preterm infants with clinically suspected sepsis and 40 healthy matched controls were assayed for serum amyloid A. In parallel, clinical and biochemical variables that are used to evaluate neonatal sepsis were compared. Forty-two episodes were diagnosed as sepsis. Serum amyloid A levels were elevated in the sepsis group (187.6 +/- 78.3 micrograms/ml), compared with infants who had no sepsis (10.2 +/- 8.3 micrograms/ml) and the control group (6.9 +/- 3.3 micrograms/ml), and were significantly higher in gram-negative compared to gram-positive sepsis (221.8 +/- 84.4 micrograms/ml vs. 48.5 +/- 22.2 micrograms/ml). Analysis of the data suggests serum amyloid A has the highest sensitivity (100%), specificity (93%) and positive predictive value (96%) for sepsis among the clinical and biochemical parameters that were tested. In conclusion, serum amyloid A seems to be a reliable early marker for the diagnosis of late-onset sepsis in preterm infants.